Rystiggo (Rozanolixizumab-Noli) Patent Expiration, LOE Window & CMS Spending

Rystiggo (Rozanolixizumab-Noli) by Ucb: Biologic BLA (Purple Book Regime), 0 AB generics, $67.6M 2024 CMS Part D & Medicaid spend, and $18,150 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorUcb
FDA Application & PathwayB761286 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$67.6M
2024 Medicare Part D Spend$56.3M
2024 Medicaid Spend$11.3M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($18,150 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for UCB across sibling Meru public-data platforms.